September 1, 2022
The Ministry of Health, Labor and Welfare (MHLW) on August 30 ordered the revision of labels for Eli Lilly’s antitumor agent Cyramza (ramucirumab) and Sanofi’s erythematosus treatment Plaquenil (hydroxychloroquine sulfate). For the Cyramza label, thrombotic microangiopathy will be added to...read more